A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study
- 1 July 2026
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Abstract
Background: Small bowel adenocarcinoma (SBA) is a rare malignancy with poor prognosis. Its clinical and pathologic characteristics are sparse, and few studies have examined its genetic features within the continuum of the gastrointestinal tract. Methods: Patients (n = 243) from six institutions with SBA and available tumor tissue underwent targeted tumor sequencing. A hidden genome classifier (HGC) was developed based on analyses of 286 gastroesophageal (foregut) and 286 colorectal (hindgut) cancers. SBA samples were assigned to foregut (n = 61), hindgut (n = 61) or mixed-type (n = 121) lineages using predefined HGC score thresholds. Overall survival (OS) was calculated from 90 days post resection until date of last follow-up for patients who underwent curative-intent resection. Results: HGC classified 54% of duodenal and 64% of intestinal-type periampullary tumors as foregut; 56% of jejunal and 68% of ileal tumors were classified as hindgut. Foregut showed amplifications in CDK12, CD3, EGFR, KRAS and cytoband changes at 8p21.1/15q26.3; hindgut harbored APC and KRAS mutations; mixed-type combined features. Median OS was 73 months (95%CI, 53 to 130) after curative-intent resection. The HGC prediction group (hindgut vs mixed-type, HR 2.80, 95%CI, 1.35-5.75) and age (HR 1.03, 95%CI, 1.01-1.05) were associated with decreased survival. Anatomic site was not associated with OS, whereas driver mutations ARID1A, KRAS and TP53 were associated with OS on univariate analysis. Conclusion: SBAs display genomic heterogeneity. The novel HGC stratifies these tumors based on homology to foregut or hindgut alterations and may be superior to anatomic location for characterizing pathology. Additional studies are needed to validate and further explore these findings.Keywords
Funding Information
- Memorial Sloan-Kettering Cancer Center (P30 CA008748-53)
- National Institutes of Health
This publication has 19 references indexed in Scilit:
- Panel gene profiling of small bowel adenocarcinoma: Results from theNADEGEprospective cohortInternational Journal of Cancer, 2020
- Using the “Hidden” genome to improve classification of cancer typesBiometrics, 2020
- Genomic Profiling of Small-Bowel AdenocarcinomaJAMA Oncology, 2017
- Treatment and Survival of Small-bowel Adenocarcinoma in the United StatesDiseases of the Colon & Rectum, 2016
- Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score–matched analysisCancer, 2015
- The consensus molecular subtypes of colorectal cancerNature Medicine, 2015
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancersAnnals of Oncology, 2011
- A single-institution experience with 491 cases of small bowel adenocarcinomaThe American Journal of Surgery, 2010
- Adenocarcinoma of the small bowelCancer, 2004